The PIK3CA gene is a linchpin in the intricate molecular network governing triple-negative breast cancer (TNBC) tumor tropism, serving as a focal point for understanding this aggressive disease. Anchored within the PI3K/AKT/mTOR signaling axis, PIK3CA mutations exert substantial influence, driving cellular processes that highlight the unique biology of TNBC. This review meticulously highlights the association between PIK3CA mutations and distinct TNBC subtypes, elucidating the gene's multifaceted contributions to tumor tropism. Molecular dissection reveals how PIK3CA mutations dynamically modulate chemokine responses, growth factor signaling, and extracellular matrix interactions, orchestrating the complex migratory behaviour characteristic of TNBC cells. A detailed exploration of PIK3CA-targeted strategies in the therapeutic arena is presented, outlining the current landscape of clinical trials and precision medicine approaches. As the scientific narrative converges, this review underscores the critical role of PIK3CA in shaping the molecular intricacies of TNBC tumor tropism and illuminates pathways toward tailored interventions, promising a paradigm shift in the clinical management of TNBC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491976 | PMC |
| http://dx.doi.org/10.1016/j.tranon.2024.102140 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulation of metastatic organotropism.
Trends Cancer
December 2024
Herbert Irving Comprehensive Cancer Center, New York, NY, 10032, USA; Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 10032, USA; Division of Digestive and Liver Diseases, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address:
Metastasis is responsible for most cancer-related deaths. Different cancers have their own preferential sites of metastases, a phenomenon termed metastatic organotropism. The mechanisms underlying organotropism are multifactorial and include the generation of a pre-metastatic niche (PMN), metastatic homing, colonization, dormancy, and metastatic outgrowth.
View Article and Find Full Text PDFExosome-Based Advances in Pancreatic Cancer: The Potential of Mesenchymal Stem Cells.
Crit Rev Oncol Hematol
December 2024
Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran; Faculty of Science, University of Amsterdam, Amsterdam, the Netherlands.
Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), is one of the most challenging clinical conditions due to its late-stage diagnosis and poor survival rates. Mesenchymal stem cells (MSCs), used for targeted therapies, are being explored as a promising treatment because of their tumor-homing properties and potential contributions to the pancreatic cancer microenvironment. Understanding these interactions is crucial for developing effective treatments.
View Article and Find Full Text PDFA hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing.
Pharmacol Res
December 2024
Department of Dermatology, University Medical Center of the Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany; Department of Medicine II, Saarland University Medical Center, Saarland University, Kirrberger Strasse 100, 66123 Saarbrücken, Germany. Electronic address:
Hepatocellular Carcinoma (HCC) is the most common form of primary liver cancer, with cirrhosis being its strongest risk factor. Interestingly, an increasing number of HCC cases is also observed without cirrhosis. We developed an HCC model via intrasplenic injection of highly tumorigenic HCC cells, which, due to cellular tropism, invade the liver and allow for a controllable disease progression.
View Article and Find Full Text PDFProtocol for generating brain metastatic tumor cells through repeated intracardiac injections in mice.
STAR Protoc
December 2024
Department of Cell Biology, School of Basic Medical Science, Southern Medical University, Guangzhou 510515, China; Department of Neurosurgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510000, China; Guangdong Province Key Laboratory of Molecular Tumor Pathology, Southern Medical University, Guangzhou 510515, China. Electronic address:
Here, we present a protocol for generating the lung cancer cell line, LLC1-BMT5, with highly brain metastatic tropism through multiple rounds of in vivo selection. We describe steps for establishing the brain metastases (BrMs) mouse model through intracardiac injection of cancer cells. We then detail procedures for obtaining brain metastatic subpopulations, in vivo selection of LLC1-BMT5 cells, and validating metastatic potential.
View Article and Find Full Text PDFLocalized light-triggered release macrophage cytopharmaceuticals containing -nitrobenzyl group for enhanced solid tumor cell-chemotherapy.
Acta Pharm Sin B
November 2024
Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Article Synopsis
- The text discusses a novel macrophage-based cytopharmaceutical called USIP@M, designed for targeted drug delivery in cancer treatment, utilizing light-triggered mechanisms for localized drug release.
- This approach involves loading amphiphilic block copolymers with specific drugs and nanoparticles, which are taken up by macrophages to exploit their natural tumor-targeting abilities.
- The cytopharmaceutical improves the immune response against tumors by polarizing macrophages, enhancing T cell immunity, and effectively killing tumors while ensuring macrophage activity is preserved.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!